SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices climb on concerns that Middle East shipping and energy-infrastructure attacks could disrupt supply. Traders are split between betting the geopolitical risk premium persists and expecting it to unwind if shipping normalizes or diplomacy advances, while many warn elevated oil could add to inflation pressure and weigh on broader markets.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Concerns about CoreWeaves debt-heavy expansion and borrowing costs, amplified by HSBCs warning that financing risks and slower AI demand could pressure growth, dominate the discussion. Bears question whether its backlog can offset funding needs, while bulls point to AI-compute demand and see the selloff as a buying or short-squeeze opportunity.

USA Rare Earth, Inc. is a domestic supplier of rare earth magnets and heavy rare earth elements. It develops a vertically integrated domestic supply chain for rare earth element magnet production, with a facility in Stillwater and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

A prolonged, steep selloff has fueled criticism of USA Rare Earths new CEO and board, with investors complaining about limited communication and questioning execution, cash burn, and potential share dilution. Some traders see the decline as an opportunity, citing the companys strategic role in domestic rare-earth supply chains and government backing, while others remain bearish amid sector-wide weakness.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention amid a steep selloff to new lows, with traders linking the pressure to weakening Trump approval and approaching midterms, as well as concerns about Truth Social and the companys limited operating business. Some view the pending TAE fusion deal as a diversification opportunity, but note that it has not yet transformed the company.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a steep post-IPO selloff, with traders pointing to successive lockup expirations and insider selling as potential supply pressure, alongside a TD Cowen price-target cut and concerns about valuation, growth and customer concentration. Bulls argue the shares are oversold and cite the companys AI hardware and backlog, while bears expect more downside; the discussion is predominantly bearish.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

Barclays downgrade and warning about commercial execution risks, particularly delays in securing a definitive TVA agreement, are driving concern around NuScales steep selloff. Traders are split between those worried the company cannot turn its reactor technology into firm projects and buyers who see the cash position and long-term nuclear demand as reasons to hold or accumulate.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is under pressure after its Q3 earnings beat failed to overcome disappointment with a full-year profit outlook that was narrowed without raising its midpoint, alongside weaker U.S. deliveries and market share. Traders debate whether the new buyback and stronger cash-flow outlook offset the cautious guidance, with some calling the selloff excessive.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforces agreement to acquire customer-engagement platform Braze is the main catalyst, with the deal expected to expand Marketing Cloud and its AI capabilities. Traders are weighing the strategic fit against the sizable cash outlay, and some are reacting negatively to CRMs weakness around the announcement.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs quarterly earnings beat and raised 2026 outlook are drawing attention, but shares are falling as traders weigh higher costs, weaker free cash flow and a loss in its insurance business against strong aerospace demand. Some see the report as a solid result, while others question whether services growth and margins can justify expectations.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is drawing attention after a broad quarterly earnings beat, raised full-year guidance, and a record backlog, reflecting strong defense and commercial aerospace demand. Traders are largely upbeat about the results, though some question how much of the guidance increase reflects cost recoveries and point to the shares weak reaction despite the strong report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call

On Thursday, Ligand Pharmaceuticals (NASDAQ:LGND) discussed second-quarter financial results during its earnings call. The full transcript is provided below.
Benzinga APIs provide real-time access to earnings callread more...

Ligand Commits Upto $47 Mln To AvenCell Cancer Cell Therapy

(RTTNews) - Thursday, Ligand Pharmaceuticals Inc. (LGND) announced a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company, for upto $47 million, helping advance the latter's pipeline, which includes AVC-201 for the treatment of relapsed/refr...

Primrose Bio Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

Primrose Bio Raises Significant Growth Capital Investment Led by Signet Healthcare Partners Primrose Bio Raises Significant Growth Capital Investment Led by Signet Healthcare PartnersPR NewswireSAN DIEGO, Sept. 22, 2026 SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a...

Here's How Much You Would Have Made Owning Ligand Pharmaceuticals Stock In The Last 5 Years

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 15.5% on an annualized basis producing an average annual return of 27.11%. Currently, Ligand Pharmaceuticals has a marketread more...

These Two Healthcare Stocks Hit Key Milestones Today – Why Is Wall Street Bullish On Them?

Equity

Orchestra BioMed received an upgrade from BTIG while LifeStance Health Group received a price target hike from Barclays.

If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 17.28% on an annualized basis producing an average annual return of 28.4%. Currently, Ligand Pharmaceuticals has a marketread more...

$100 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 15 years by 14.91% on an annualized basis producing an average annual return of 28.27%. Currently, Ligand Pharmaceuticals has a marketread more...

Ligand Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Ligand Pharmaceuticals Inc (Symbol: LGND) have crossed above the average analyst 12-month target price of $301.78, changing hands for $303.39/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down...

In recent trading, shares of Ligand Pharmaceuticals Inc (Symbol: LGND) have crossed above the average analyst 12-month target price of $271.00, changing hands for $274.88/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down...

Ligand Pharmaceuticals Director Unloads 2,501 Shares  Should You Be Concerned?

Key PointsKozarich sold 2,501 common shares...

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Bullish Sentiment

<ul class="summary-bullets"><li>BTIG turned “more constructive” on OBIO after management indicated the Backbeat trial remains on track to complete enrollment.</li><li>The trial is testing a therapy in patients with uncontrolled high blood pressure who need a pacemaker.</li><li>Barclays said LFST shareholders’ offering helps reduce the overhang from private equity ownership.</li></ul>Orchestra BioMed (OBIO) and LifeStance Health Group (LFST) were in focus on Thursday, with the stocks breaching their 52-week highs as Wall Street turned more positive on both healthcare stocks.Analysts cited progress toward a key clinical milestone at Orchestra and a reduction in LifeStance’s private-equity ownership overhang.At the time of writing, <a href="https://stocktwits.com/symbol/LFST">LFST shares</a> were up more than 4% and trading at the levels last seen in November 2021, while <a href="https://stocktwits.com/symbol/OBIO">OBIO shares</a> surged 11% to their highest levels since February 2025.<h2 class="st-heading-2">BTIG Sees Over 40% Potential Upside In OBIO</h2>Orchestra BioMed received an upgrade from BTIG on Thursday as the medical-device company approaches a key milestone for its late-stage hypertension study.BTIG analyst Marie Thibault upgraded Orchestra to ‘Buy’ from ‘Neutral’ with a $10 price target, representing more than 40% upside from current levels. The firm said it has become “more constructive” after management indicated the Backbeat trial remains on track to complete enrollment around the end of the third quarter.The trial, being conducted in partnership with Medtronic (MDT), is testing a therapy in patients with uncontrolled high blood pressure who need a pacemaker. Orchestra is targeting to enroll 284 patients, with primary results expected in the second quarter of 2027.BTIG said Orchestra has now met several conditions it previously required before upgrading the stock, including staying on schedule and securing non-dilutive funding.The company received <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.orchestrabiomed.com/news-releases/news-release-details/orchestra-biomed-receives-20-million-payment-medtronic-under">$35 million</a> in strategic capital earlier this year, including $20 million from Medtronic and <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.orchestrabiomed.com/news-releases/news-release-details/orchestra-biomed-receives-15-million-investment-ligand-under?">$15 million</a> from Ligand&nbsp;Pharmaceuticals (LGND).&nbsp;Orchestra ended June with $110 million in cash and investments, which it <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.orchestrabiomed.com/news-releases/news-release-details/orchestra-biomed-reports-second-quarter-2026-financial-results">expects</a> will fund operations into the fourth quarter of 2027.Retail sentiment surrounding OBIO on Stockwits turned ‘bullish’ from ‘bearish.’ The stock has gained around 40% so far this year.<h2 class="st-heading-2">Barclays Says LFST Stock Offering Reduces Private Equity Ownership Overhang</h2>LifeStance Health Group received a price target hike from Barclays on Thursday, a day after existing shareholders launched a secondary share offering.Barclays raised its price target on LifeStance to $15 from $13 and maintained an ‘Overweight’ rating, according to The Fly. This represents a 13% upside from current levels.On Wednesday, selling shareholders priced an offering of 22.25 million LifeStance shares at $12.35 per share, valuing the transaction at approximately $275 million. The offering price was at a 3.5% discount to the stock’s closing price of $12.80 on Tuesday.Barclays said the offering helps reduce the overhang from private equity ownership and added that LifeStance continues to execute well.Notably, LifeStance is not selling shares in the offering and will not receive any proceeds, which will instead go to the selling shareholders.Retail sentiment surrounding LFST on Stockwits turned ‘bullish’ from ‘neutral.’ The stock has surged 88% so far in 2026.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/compass-ceo-robert-reffkin-says-upcoming-open-ai-anthropic-ip-os-are-already-boosting-luxury-housing-beyond-san-francisco/cZta1LyRJ6B">Compass CEO Robert Reffkin Says Upcoming OpenAI, Anthropic IPOs Are Already Boosting Luxury Housing Beyond San Francisco</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trending stock. (Photo Courtesy of Flavio Coelho via Getty Images)

LifeStance Health Group Inc

Medtronic Plc

Orchestra BioMed Holdings Inc

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$297.28
Prev Close	$295.54
Open	$300.41
Dividend Yield	0.00%
50-Day Moving Average	$292.53
Beta	1.01
Avg. Volume	255,932.97
PE Ratio	31.78

52-Week High	$326.63
52-Week Low	$175.89
Market Capitalization	$5.93B
EPS (Annual)	$6.13
Price to Book	6.12
Revenue Per Employee	$5.7M

Feed

News

Sentiment

Earnings

Fundamentals

Info

LGND Fundamentals